CN103585190B - Wall tapestry extract is preparing the application in medicines resistant to liver cancer - Google Patents
Wall tapestry extract is preparing the application in medicines resistant to liver cancer Download PDFInfo
- Publication number
- CN103585190B CN103585190B CN201310525674.9A CN201310525674A CN103585190B CN 103585190 B CN103585190 B CN 103585190B CN 201310525674 A CN201310525674 A CN 201310525674A CN 103585190 B CN103585190 B CN 103585190B
- Authority
- CN
- China
- Prior art keywords
- wall tapestry
- extract
- tapestry extract
- wall
- obtains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000284 extract Substances 0.000 title claims abstract description 139
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 229940079593 drug Drugs 0.000 title claims abstract description 30
- 201000007270 liver cancer Diseases 0.000 title claims abstract description 25
- 208000014018 liver neoplasm Diseases 0.000 title claims abstract description 25
- 239000011347 resin Substances 0.000 claims abstract description 19
- 229920005989 resin Polymers 0.000 claims abstract description 19
- 239000000341 volatile oil Substances 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 57
- 238000000605 extraction Methods 0.000 claims description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 17
- 238000010438 heat treatment Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 230000000274 adsorptive effect Effects 0.000 claims description 9
- 230000001476 alcoholic effect Effects 0.000 claims description 9
- 239000006286 aqueous extract Substances 0.000 claims description 9
- 239000012141 concentrate Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 239000003480 eluent Substances 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 238000001256 steam distillation Methods 0.000 claims description 9
- 239000003463 adsorbent Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 abstract description 4
- 238000000746 purification Methods 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 25
- 206010028980 Neoplasm Diseases 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 8
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 239000002574 poison Substances 0.000 description 5
- 229960001674 tegafur Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 208000037920 primary disease Diseases 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001644 anti-hepatocarcinoma Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 241000202726 Bupleurum Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 108010042653 IgA receptor Proteins 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- -1 and dry Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000009519 fu-yuan Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of novelty teabag of wall tapestry extract, this novelty teabag is that wall tapestry extract is preparing the application in medicines resistant to liver cancer.Described wall tapestry extract is prepared as follows: take wall tapestry as raw material, extract volatile oil, and adopt purification with macroreticular resin technology to obtain wall tapestry extract A, wall tapestry extract B, wall tapestry extract C respectively, mix by a certain percentage, be wall tapestry extract.Wall tapestry extract provided by the present invention is significant to preparing medicines resistant to liver cancer.
Description
Technical field
The invention belongs to biomedicine field, relate to a kind of Chinese medicinal material extract and preparing the application in medicines resistant to liver cancer, specifically relate to wall tapestry extract and preparing the application in medicines resistant to liver cancer.
Background technology
According in February, 2010 Ministry of Public Health statistics, annual global number of cancer deaths reaches 1,000 ten thousand.The reason of current global 1/4th human mortalities is caused by cancer, and prediction is gone down by current trend development, is owing to having suffered from cancer to the year two thousand fifty by there being the died of 1/2nd.The pernicious cancer morbidity of China, with annual 2.5-5% speed increment, has become the arch-criminal of serious harm human life.Higher with sickness rate such as hepatocarcinoma in the middle of various types of cancer.
Hepatocarcinoma refers to the malignant tumor betiding liver, comprises primary hepatocarcinoma and secondary liver cancer two kinds, and mostly what the hepatocarcinoma of the daily theory of people referred to is primary hepatocarcinoma.Primary hepatocarcinoma is one of modal malignant tumor clinically, and according to recent statistics, liver cancer patient about 600,000 is newly sent out in the whole world every year, occupies the 5th of malignant tumor.Primary hepatocarcinoma can be divided into Hepatocellular carcinoma, intrahepatic cholangiocarcinoma and mixed carcinoma of liver by cell typing.Nodular type, massive type and diffuse type can be divided into by the form of tumor.Primary hepatocarcinoma belongs to high morbidity in China, and general male is more than women.China is hepatitis B big country, and the hepatocarcinoma of China is many to be developed on the basis of hbv-liver cirrhosis, and hepatitis C patient is also increasing gradually, also can develop into hepatocarcinoma after hepatitis B.Current China number of the infected accounts for the more than half of the whole world, and account for 55% of global hepatocarcinoma patient, become a large killer of serious threat our people health and lives, its danger can not look down upon.Hepatocarcinoma can betide any age, but is many with 31 ~ 50 years old, and the ratio of men and women is about 8:1.More than 90% belong to when making a definite diagnosis in, late period, surgical engine can many miss, so adopt modern comprehensive treatment to be often subject to a definite limitation because of Radiotherapy chemotherapy and immunization therapy; And Radiotherapy chemotherapy is very big to the treatment toxicity of primary disease, indication then reduces, and curative effect is also poor; Though interventional therapy has certain curative effect, need quite high condition and equipment, spend also larger.Therefore Chinese medicine one of essential therapeutic arsenals becoming primary disease.Chinese medicine also with Radiotherapy chemotherapy fit applications, preferably " attenuation synergistic " effect can be played.
The cause of disease of the treatment by Chinese herbs hepatocarcinoma of hepatocarcinoma, doctor trained in Western medicine thinks mainly relevant with chronic hepatic diseases, aflatoxin, parasite, excessive drinking, inherited genetic factors.In China, the factor maximum with onset of liver cancer rate relation is hepatitis B virus, particularly HBsAg positive.Therefore, HBsAg positive and patients with chronic liver are listed in the high-risk group of hepatocarcinoma.Have research to think, HBsAg has directly carcinogenic possibility, and is not necessarily by this interstage of chronic hepatopathy.
The traditional Chinese medical science thinks that primary disease loses primarily of internal organs asthenia of qi and blood, insufficiency of the spleen wet poly-, the expectorant blood coagulation stasis of blood; The evil poison invasion of six climate exopathogens, evil solidifying poison knot, internal injury caused by excess of seven emotions, depressed emotion etc., can make gas, blood, wet, heat, the stasis of blood, poison tie mutually and form hepatocarcinoma.Primary disease disease located in liver, closely related with spleen, gallbladder, stomach, main pathogenesis is weakened body resistance in interior, and evil poison pents up.In treatment, by determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, main point of following four types: the treatment by Chinese herbs depression of liver-QI of hepatocarcinoma, square medicine selects bupleurum powder for relieving liver-qi to add and subtract; Qi depression to blood stasis, selects Fuyuan Huoxue Tangization to cut out; Damp and hot poly-poison, Herba Artemisiae Scopariae Decoction is added and subtracted; Deficiency and exhaustion of liver-YIN, square medicine is selected YIGUANJIAN to close xijiao Dihuang Tangization and is cut out.
Wall tapestry is the dry thallus of lichens Teloshistaceae plant wall tapestry Theloschestes flavicans (Sw.) Norm.After collection, removing earth, dries.Record in " Drug Standard of Ministry of Public Health of the Peoples Republic of China Tibetan medicine (first) ", standard number: WS3-BC-0125-95.Cool in nature, bitter in the mouth.There is heat extraction, effect of removing toxic substances.For lung-heat, liver-heat, arteries and veins heat, scorchingly hot.The common drug of the minority areas such as illiteracy is hidden for China.But about the basic research of wall tapestry is still very limited, the follow-up promotion and application of this medical material are restricted.Relevant wall tapestry chemical composition and pharmacological research have no report.
Domestic patent search result, has no wall tapestry Patents.
Above-mentioned document and patent etc., there is not yet wall tapestry or the wall tapestry extract report for the preparation of medicines resistant to liver cancer.
Summary of the invention
Wall tapestry extract is the object of the present invention is to provide to prepare the application in medicines resistant to liver cancer.
The present invention is achieved through the following technical solutions:
The present invention's wall tapestry used is the dry thallus for lichens Teloshistaceae plant wall tapestry Theloschestes flavicans (Sw.) Norm.
Wall tapestry extract of the present invention is preparing the application in medicines resistant to liver cancer, and the preparation method of described wall tapestry extract is:
(1) wall tapestry, adds 8-15 times of water, soaks 4-12 hour, adopts extraction by steam distillation volatile oil, extraction time 1-4 hour, extraction time 1-3 time, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtains extracting solution A and medicinal residues A respectively;
(2) step (1) being obtained medicinal residues A concentration 50%-95% ethanol is solvent, heating and refluxing extraction, and extraction time is 1-3 time, and each extraction time is 1-3 hour, each solvent load is 8-15 times of wall tapestry weight, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) by the extracting solution A that step (1) obtains, be concentrated into relative density d=1.10-1.20, pass through macroporous adsorptive resins, first wash with water, then use the alcoholic solution eluting of concentration 50%-70%, collect different concentration ethanol eluent, concentrate drying, obtains wall tapestry extract C;
(4) above-mentioned wall tapestry extract A, wall tapestry extract B, wall tapestry extract C, wherein one or both or three kinds mix by a certain percentage, obtain wall tapestry extract of the present invention.
The preparation method of wall tapestry extract is:
(1) wall tapestry, adds 8-15 times of water, soaks 4-12 hour, adopts extraction by steam distillation volatile oil, extraction time 1-4 hour, extraction time 1-3 time, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtains extracting solution A and medicinal residues A respectively;
(2) step (1) being obtained medicinal residues A concentration 50%-95% ethanol is solvent, heating and refluxing extraction, and extraction time is 1-3 time, and each extraction time is 1-3 hour, each solvent load is 8-15 times of wall tapestry weight, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) by the extracting solution A that step (1) obtains, be concentrated into relative density d=1.10-1.20, pass through macroporous adsorptive resins, first wash with water, then use the alcoholic solution eluting of concentration 50%-70%, collect different concentration ethanol eluent, concentrate drying, obtains wall tapestry extract C;
(4) by above-mentioned wall tapestry extract A, wall tapestry extract B, the mixing of wall tapestry extract C, wall tapestry extract of the present invention is obtained.
The preparation method of preferred wall tapestry extract is:
(1) wall tapestry, adds 12 times of water, soaks 8 hours, adopts extraction by steam distillation volatile oil, 2 hours extraction times, extraction time 2 times, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtains extracting solution A and medicinal residues A respectively;
(2) step (1) being obtained medicinal residues A 70% ethanol is solvent, heating and refluxing extraction, and extraction time is 2 times, and each extraction time is 2 hours, each solvent load is 12 times of wall tapestry weight, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) by the extracting solution A that step (1) obtains, be concentrated into relative density d=1.15, by D101 macroporous adsorptive resins, first wash with water, then use the alcoholic solution eluting of concentration 60%, collect 60% concentration ethanol eluent, concentrate drying, obtain wall tapestry extract C;
(4) by above-mentioned wall tapestry extract A, wall tapestry extract B, the mixing of wall tapestry extract C, wall tapestry extract of the present invention is obtained.
The preparation method of wall tapestry extract of the present invention, is characterized in that: the macroporous adsorbent resin adopted is D101 macroporous adsorbent resin, HPD600 macroporous adsorbent resin, DM130 macroporous adsorbent resin.
Wall tapestry extract of the present invention, by adding the various adjuvants that pharmaceutics allows, makes the peroral dosage forms such as the tablet on pharmaceutics, granule, capsule.
Wall tapestry extract of the present invention and wall tapestry extract A, wall tapestry extract B, wall tapestry extract C are preparing the application in medicines resistant to liver cancer.
Wall tapestry extract of the present invention and chemical drugs or Chinese medicine or natural drug form medicines resistant to liver cancer.
Wall tapestry extract A of the present invention, wall tapestry extract B, wall tapestry extract C and chemical drugs or Chinese medicine or natural drug form medicines resistant to liver cancer.
The present invention adopts purification with macroreticular resin technology to wall tapestry first, and preparation has the extract of resisting liver cancer activity, and preparation technology is easy and simple to handle, and production cost is low, is suitable for industrialized great production.
The present invention's exploratory development is first that raw material extracts the anti-hepatocarcinoma extract of preparation with the dry thallus of lichens Teloshistaceae plant wall tapestry Theloschestes flavicans (Sw.) Norm.Pharmacological tests shows, wall tapestry extract each group of tumor mass reduction compared with model group, and medication two weeks wall tapestry extract each treatment group tumor tissue P53 express and significantly decline; Macrophage CD
68testing result is shown: wall tapestry extract group compares with model control group, has extremely significant difference (P<0.01).
Detailed description of the invention
Below by specific experiment example and embodiment, wall tapestry extract is described further preparing the application in medicines resistant to liver cancer, but is not limited to the present invention.
Embodiment 1: the preparation of wall tapestry extract
(1) wall tapestry 25kg, adds 12 times of water, soaks 8 hours, adopts extraction by steam distillation volatile oil, 2 hours extraction times, extraction time 2 times, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtains extracting solution A and medicinal residues A respectively;
(2) step (1) being obtained medicinal residues A concentration 70% ethanol is solvent, heating and refluxing extraction, and extraction time is 2 times, and each extraction time is 2 hours, each solvent load is 12 times of wall tapestry weight, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) by the extracting solution A that step (1) obtains, be concentrated into relative density d=1.15, by D101 macroporous adsorptive resins, first wash with water, then use the alcoholic solution eluting of concentration 60%, collect 60% concentration ethanol eluent, concentrate drying, obtain wall tapestry extract C;
(4) above-mentioned wall tapestry extract A, wall tapestry extract B and wall tapestry extract C are mixed, obtain wall tapestry extract of the present invention.
Embodiment 2: the preparation of wall tapestry extract
(1) wall tapestry, adds 15 times of water, soaks 4 hours, adopts extraction by steam distillation volatile oil, 4 hours extraction times, extraction time 1 time, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtains extracting solution A and medicinal residues A respectively;
(2) step (1) being obtained medicinal residues A 50% ethanol is solvent, heating and refluxing extraction, and extraction time is 1 time, and each extraction time is 1 hour, each solvent load is 8 times of wall tapestry weight, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) by the extracting solution A that step (1) obtains, relative density d=1.20 is concentrated into, by HPD600 macroporous adsorptive resins, first wash with water, then use the alcoholic solution eluting of concentration 70%, collect 70% concentration ethanol eluent, concentrate drying, obtains wall tapestry extract C;
(4) by above-mentioned wall tapestry extract A, wall tapestry extract B, the mixing of wall tapestry extract C, wall tapestry extract of the present invention is obtained.
Embodiment 3: the preparation of wall tapestry extract
(1) wall tapestry, adds 8 times of water, soaks 12 hours, adopts extraction by steam distillation volatile oil, 1 hour extraction time, extraction time 3 times, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtains extracting solution A and medicinal residues A respectively;
(2) step (1) being obtained medicinal residues A 95% ethanol is solvent, heating and refluxing extraction, and extraction time is 3 times, and each extraction time is 3 hours, each solvent load is 15 times of wall tapestry weight, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) by the extracting solution A that step (1) obtains, relative density d=1.10 is concentrated into, by DM130 macroporous adsorptive resins, first wash with water, then use the alcoholic solution eluting of concentration 50%, collect 50% concentration ethanol eluent, concentrate drying, obtains wall tapestry extract C;
(4) above-mentioned wall tapestry extract A, wall tapestry extract B and wall tapestry extract C are mixed, obtain wall tapestry extract of the present invention.
Embodiment 4: the preparation of wall tapestry extract tablet
Example 2 wall tapestry extract 335g, adds starch 110g, mixing, granulates, dry, sieves, adds microcrystalline Cellulose 48g, magnesium stearate 4.5g, and mixing, is pressed into 1000, obtains wall tapestry extract tablet.
Embodiment 5: the preparation of wall tapestry extract particles agent
Example 2 wall tapestry extract 240g, adds dextrin 150g, mixing, granulates, and dry, granulate, obtains the agent of wall tapestry extract particles.
Embodiment 6: the preparation of wall tapestry extract capsule
Example 3 wall tapestry extract 305g, adds starch 85g, mixing, granulates, dry, sieves, adds magnesium stearate 4g, and mixing, obtains wall tapestry extract capsule by encapsulated 1000.
Experimental example 1: the anti-hepatocarcinoma test of wall tapestry extract
1.1 material
Laboratory animal: healthy ICR mice 70, male, body weight 20 ± 2 g (Xi'an Jiaotong University Medical College's Experimental Animal Center provides), 28 ~ 30d.Credit number: SCXK (Shan) 2011-001.
Experiment tumor strain: mouse liver cell carcinoma strain (H
22) provided by The Fourth Military Medical University's university animal experimental center.
Medicine: prepare wall tapestry extract, wall tapestry extract A, wall tapestry extract B by the embodiment of the present invention 1 method, (lot number is respectively wall tapestry extract C: 20111011,20111012,20111013,20111014).Tegafur Tablet (FT-207), Shanghai Hua Lian pharmaceutical factory of Pharmaceutical Group company limited, the accurate word of traditional Chinese medicines: H31021668 lot number: 110905.
Main agents: P53 protein B A0133 multi-resistance, immunohistochemical staining test kit, Wuhan doctor's moral Bioisystech Co., Ltd provides.Rabbit anti-mouse macrophage polyclonal antibody (SnataCurz, USA); CD
68immunohistochemical staining test kit, Wuhan doctor's moral Bioisystech Co., Ltd provides.Bioactivation element sheep anti-mouse igg BA0523,
DAB developer, immunohistochemical kit, all purchased from Wuhan Boster Biological Technology Co., Ltd.; 0.02% trypan blue, PBS liquid 0.01m citric acid salt buffer, 95% ethanol, formaldehyde, dimethylbenzene, hydrogen peroxide, pure water provide by ShanXi Chinese Medicine Academy Pathological Staff Room.
Major experimental instrument: superclean bench (Suzhou Decontamination Equipment Plant), cycle type histotome (2135 type Germany), optical microscope (Chongqing optical instrument factory), electronic balance (Shanghai second analytical tool factory), horizontal centrifuge (LD-42 type, Beijing Medical Centrifugal Machine Factory), electro-heating standing-temperature cultivator (Shanghai Medical Apparatus and Instruments Factory, HH Bll42), cryogenic refrigerator one (refrigerator factory of Haier, Qingdao), microscope slide, coverslip (the raw instrument of the sub-honorization in Shanghai), true color Pathologic image analysis system (Xiamen company of Mike Audi), CCD photographing unit, Jiangsu Jetta morphological analysis software (EJDASOID), microwave oven one (LG Electrical Appliances Co., Ltd), centrifuge tube, wet box etc.
1.2 experimental technique
The making of animal model: randomly draw 10 mices and do outside Normal group, makes for all the other 40 and touches, rat liver cancer H
22the strain of hepatocarcinoma tumor tumor, extracts tumor liquid under aseptic condition, centrifugal (1500r/min × 2min), and adjustment cell concentration is to every milliliter of many 2 × 10m of suspension
2oncocyte, then use 0.25mL syringe with 0.2mL/ only, the right armpit subcutaneous vaccination of mice, it is 100% that the success rate of touching is made in this experiment.Experiment is divided into groups and administration: after modeling, 24h is except normal blank matched group, and mice is divided into 4 groups at random, divides into groups to start gastric infusion the same day, the equal successive administration 14d of each group: Normal group: with normal saline 0.2mL//d; Model control group: with normal saline 0.2mL//d; Ftorafur group: give 0.2mL//d; The aqueous solution that the Tegafur Tablet of 10 times of (containing ftorafur 4.0mg/mL) quantities of being grown up is made; Wall tapestry extract, wall tapestry extract A, wall tapestry extract B, wall tapestry extract C, equal gavage, 0.2mL/, 1 time/d.
2 experimental results
2.1 tumor-inhibiting action
in table 1.
Table 1 H
22the impact of liver cancer mouse tumor weight and tumour inhibiting rate
2.2 saltant type P53 and macrophage CD
68mensuration in table 2.
The expression of mutated P53 gene after the administration of table 2 each group
Note: compare with model control group
△p<0.05,
▲p<0.01; Compare with normal control
◇p<0.01.
2.3 CD
68mensuration in table 3.
Table 3 is group liver cancer mouse macrophage CD respectively
68expression
Note: compare with model control group
△p<0.05,
▲p<0.01; Compare with normal control
◇p<0.01.
This experiment Immunohistochemical Method detects H
22the expression of hepatoma carcinoma cell mutant P 53 protein can react the situation of P53 gene mutation.Result display model group mouse mutant P53 Overexpression, is significantly higher than ftorafur positive controls and wall tapestry extract group, illustrates that wall tapestry extract can the expression of mutation inhibiting type P53 gene.Wall tapestry extract can make the expression of apoptosis suppressor saltant type P53 obviously reduce, show wall tapestry extract energy direct killing oncocyte, inhibition tumor cell is bred, liver cancer apoptosis reducing, its mechanism of action may be expressed with suppressor gene p53 to be increased, the expression of hepatocarcinoma apoptosis suppressor saltant type P53 can be reduced, promote that apoptotic generation is relevant.
Wall tapestry extract group compares with ftorafur group, and both tumour inhibiting rates are that the former is not so good as the latter, but the latter has shown certain effective tumour inhibiting rate; Wall tapestry extract of the present invention not only has certain tumor-inhibiting action and antineoplastic invasion and transfer, and can significantly improve the phagocytic function of macrophage.This is just in time consistent with " healthy energy deposit in, heresy can not be done " of the traditional Chinese medical science.
Claims (8)
1. wall tapestry extract is preparing the application in medicines resistant to liver cancer, and the preparation method of described wall tapestry extract is:
(1) wall tapestry, adds 8-15 times of water, soaks 4-12 hour, adopts extraction by steam distillation volatile oil, extraction time 1-4 hour, extraction time 1-3 time, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtains extracting solution A and medicinal residues A respectively;
(2) step (1) being obtained medicinal residues A concentration 50%-95% ethanol is solvent, heating and refluxing extraction, and extraction time is 1-3 time, and each extraction time is 1-3 hour, each solvent load is 8-15 times of wall tapestry weight, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) by the extracting solution A that step (1) obtains, be concentrated into relative density d=1.10-1.20, pass through macroporous adsorptive resins, first wash with water, then use the alcoholic solution eluting of concentration 50%-70%, collect different concentration ethanol eluent, concentrate drying, obtains wall tapestry extract C;
(4) above-mentioned wall tapestry extract A, wall tapestry extract B, wall tapestry extract C, wherein one or both or three kinds mix by a certain percentage, obtain wall tapestry extract.
2. application according to claim 1, is characterized in that the preparation method of described wall tapestry extract is:
(1) wall tapestry, adds 8-15 times of water, soaks 4-12 hour, adopts extraction by steam distillation volatile oil, extraction time 1-4 hour, extraction time 1-3 time, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtains extracting solution A and medicinal residues A respectively;
(2) step (1) being obtained medicinal residues A concentration 50%-95% ethanol is solvent, heating and refluxing extraction, and extraction time is 1-3 time, and each extraction time is 1-3 hour, each solvent load is 8-15 times of wall tapestry weight, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) by the extracting solution A that step (1) obtains, be concentrated into relative density d=1.10-1.20, pass through macroporous adsorptive resins, first wash with water, then use the alcoholic solution eluting of concentration 50%-70%, collect different concentration ethanol eluent, concentrate drying, obtains wall tapestry extract C;
(4) by above-mentioned wall tapestry extract A, wall tapestry extract B, the mixing of wall tapestry extract C, wall tapestry extract is obtained.
3. application according to claim 1, is characterized in that the preparation method of described wall tapestry extract is:
(1) wall tapestry, adds 12 times of water, soaks 8 hours, adopts extraction by steam distillation volatile oil, 2 hours extraction times, extraction time 2 times, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtains extracting solution A and medicinal residues A respectively;
(2) step (1) being obtained medicinal residues A 70% ethanol is solvent, heating and refluxing extraction, and extraction time is 2 times, and each extraction time is 2 hours, each solvent load is 12 times of wall tapestry weight, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) by the extracting solution A that step (1) obtains, be concentrated into relative density d=1.15, by D101 macroporous adsorptive resins, first wash with water, then use the alcoholic solution eluting of concentration 60%, collect 60% concentration ethanol eluent, concentrate drying, obtain wall tapestry extract C;
(4) by above-mentioned wall tapestry extract A, wall tapestry extract B, the mixing of wall tapestry extract C, wall tapestry extract is obtained.
4. according to application according to claim 1 or claim 2, it is characterized in that: the macroporous adsorbent resin adopted is D101 macroporous adsorbent resin or HPD600 macroporous adsorbent resin or DM130 macroporous adsorbent resin.
5. application according to claim 1, is characterized in that described wall tapestry extract makes tablet oral on pharmaceutics, granule, capsule by the various adjuvants adding pharmaceutics permission.
6. application according to claim 1, is characterized in that described wall tapestry extract A, wall tapestry extract B, wall tapestry extract C are preparing the application in medicines resistant to liver cancer.
7. application according to claim 1, is characterized in that described wall tapestry extract A, wall tapestry extract B, wall tapestry extract C and chemical drugs or Chinese medicine or natural drug form medicines resistant to liver cancer.
8. application according to claim 1, is characterized in that described wall tapestry extract and chemical drugs or Chinese medicine or natural drug form medicines resistant to liver cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310525674.9A CN103585190B (en) | 2013-10-31 | 2013-10-31 | Wall tapestry extract is preparing the application in medicines resistant to liver cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310525674.9A CN103585190B (en) | 2013-10-31 | 2013-10-31 | Wall tapestry extract is preparing the application in medicines resistant to liver cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103585190A CN103585190A (en) | 2014-02-19 |
| CN103585190B true CN103585190B (en) | 2015-10-28 |
Family
ID=50075644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310525674.9A Expired - Fee Related CN103585190B (en) | 2013-10-31 | 2013-10-31 | Wall tapestry extract is preparing the application in medicines resistant to liver cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103585190B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1698769A (en) * | 2005-05-17 | 2005-11-23 | 重庆医药工业研究院有限责任公司 | Bupleurum root soft capsule and its preparation method |
| CN102671017A (en) * | 2012-04-27 | 2012-09-19 | 湖北长友现代农业股份有限公司 | Method for simultaneously preparing indocalamus leaf volatile oil, total flavone and total polysaccharide |
-
2013
- 2013-10-31 CN CN201310525674.9A patent/CN103585190B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1698769A (en) * | 2005-05-17 | 2005-11-23 | 重庆医药工业研究院有限责任公司 | Bupleurum root soft capsule and its preparation method |
| CN102671017A (en) * | 2012-04-27 | 2012-09-19 | 湖北长友现代农业股份有限公司 | Method for simultaneously preparing indocalamus leaf volatile oil, total flavone and total polysaccharide |
Non-Patent Citations (3)
| Title |
|---|
| "Lichen-derived Culture and Its Pharmaceutical Applications";Yoshikazu Yamamoto;《International Symposium on Systematic Lichenology Bryology》;20101021;82-85 * |
| "地衣化学成分和药理作用研究进展";房敏峰 等;《中草药》;20111231;第42卷(第12期);2571-2576 * |
| "地衣抗生素和地衣多糖类物质的研究进展";张璞 等;《山东科学》;20070430;第20卷(第2期);41-44 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103585190A (en) | 2014-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101310751B (en) | Detection method of medicine composition for replenishing qi and blood | |
| CN106236801A (en) | Pseudo-ginseng activity medicine that super-micro wall-broken crushing technology is made and health product and preparation method thereof | |
| Ruan et al. | Mechanism of Nicotiflorin in San-Ye-Qing rhizome for anti-inflammatory effect in ulcerative colitis | |
| CN103585209B (en) | Dorema ammoniacum resin extract is preparing the application in medicines resistant to liver cancer | |
| CN103405487B (en) | Chinese medicine compound effective part with effect of treating arthritis | |
| Qin et al. | Corydalis saxicola Bunting: A review of its traditional uses, phytochemistry, pharmacology, and clinical applications | |
| CN104800236B (en) | Asarum total polysaccharide extract with antitussive activity and its extraction method and application | |
| Liang et al. | Effect of Chinese herbal compound on liver fibrosis in rabbits with schistosomiasis by B-ultrasound | |
| CN103585190B (en) | Wall tapestry extract is preparing the application in medicines resistant to liver cancer | |
| CN102772554A (en) | Traditional Chinese medicine compound for curing schizophrenia | |
| CN102018747B (en) | Application of red stilbene and red stilbene polysaccharide in preparing medicament for improvement of learning memory and treatment of Alzheimer disease | |
| CN116173164A (en) | Traditional Chinese medicine composition for treating liver cancer and postoperative radiotherapy and chemotherapy and preparation method thereof | |
| CN101904894B (en) | Application of lamiophlomis rotate total glycosides in preparing medicines | |
| CN104688723A (en) | Application of anhydroicaritin in preparation of medicine for treating anaemia | |
| CN104473936A (en) | Pharmaceutical composition used for treating liver cancer | |
| CN104523726A (en) | Pharmaceutical composition for treating liver cancer | |
| CN104473949A (en) | Pharmaceutical composition used for treating liver cancer | |
| CN104510749A (en) | Pharmaceutical composition for treating liver cancer | |
| CN103239506A (en) | Tongmai oral liquid raw material extract | |
| CN101816702B (en) | Lung cancer preventing and treating composition extracted from selfheal and/or garden orache and application thereof in preparation of lung cancer preventing and treating medicine | |
| CN101926929A (en) | Traditional Chinese medicine for treating vascular dementia and preparation method thereof | |
| CN104523704A (en) | Pharmaceutical composition for treating liver cancer | |
| CN110772610A (en) | A kind of plant extract and its preparation method and application | |
| Cheng et al. | Cynanchum paniculatum (Bunge) Kitag. ex H. Hara inhibits pancreatic cancer progression by inducing caspase-dependent apoptosis and suppressing TGF-β-mediated epithelial-mesenchymal transition | |
| Liu et al. | Concomitant administration of lenvatinib and camrelizumab for the treatment of hepatocellular carcinoma, and its effect on hepatocellular carcinoma control |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: YU SHUJUAN Free format text: FORMER OWNER: JINAN XINGYI MEDICAL TECHNOLOGY CO., LTD. Effective date: 20150907 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yu Shujuan Inventor before: Kong Qianqian |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: KONG QIANQIAN TO: YU SHUJUAN |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150907 Address after: 265100 No. 5, building 21, building 36, No. 401, Hai Dao Road, Haiyang, Shandong, Yantai Applicant after: Yu Shujuan Address before: 250101 No. 51 Industrial South Road, Ji'nan hi tech Zone, Shandong, Ji'nan Applicant before: Jinan Xingyi Medical Technology Co.,Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151028 Termination date: 20161031 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |